PharmacoDB

Description: High throughput drug screening technologies have enabled the profiling of hundreds of cancer cell lines to a large variety of small molecules to discover novel and repurposed treatments. Several large studies have been publicly released testing candidate molecules, often with corresponding molecular profiles of the cell lines used for drug screening. These studies have become invaluable resources for the research community, allowing researchers to leverage the collected data to support their own research. However, such pharmacogenomic datasets are disparate and lack of standardization for cell line and drug identifiers, and used heterogeneous data format for the drug sensitivity measurements.